购物车
- 全部删除
- 您的购物车当前为空
Tuvusertib (M1774) 是一种可口服的共济失调毛细血管扩张和 Rad3相关(ATR)激酶抑制剂(Ki< 1 µΜ),具有选择性和潜在的抗肿瘤活性。Tuvusertib 选择性抑制 ATR 活性,阻断丝氨酸/苏氨酸蛋白激酶检查点激酶1 (CHK1)的下游磷酸化,从而抑制 DNA 损伤检查点激活,破坏 DNA 损伤修复,诱导肿瘤细胞凋亡。
为众多的药物研发团队赋能,
让新药发现更简单!
Tuvusertib (M1774) 是一种可口服的共济失调毛细血管扩张和 Rad3相关(ATR)激酶抑制剂(Ki< 1 µΜ),具有选择性和潜在的抗肿瘤活性。Tuvusertib 选择性抑制 ATR 活性,阻断丝氨酸/苏氨酸蛋白激酶检查点激酶1 (CHK1)的下游磷酸化,从而抑制 DNA 损伤检查点激活,破坏 DNA 损伤修复,诱导肿瘤细胞凋亡。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 475 | 现货 | |
5 mg | ¥ 1,150 | 现货 | |
10 mg | ¥ 1,780 | 现货 | |
25 mg | ¥ 3,470 | 现货 | |
50 mg | ¥ 4,930 | 现货 | |
100 mg | ¥ 6,850 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 1,290 | 现货 |
产品描述 | Tuvusertib (M1774) is an orally available ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor (Ki< 1 µΜ) with selective and potentially antitumor activity.Tuvusertib selectively inhibits ATR activity and blocks downstream phosphorylation of serine/threonine protein kinase checkpoint kinase 1 (CHK1), thereby inhibits DNA damage checkpoint activation, disrupting DNA damage repair and inducing apoptosis in tumor cells. |
别名 | M1774, ATR inhibitor 1 |
分子量 | 370.32 |
分子式 | C16H12F2N8O |
CAS No. | 1613200-51-3 |
存储 | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
溶解度信息 | DMSO: 6.25 mg/mL (16.88 mM), Sonication is recommended. | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.